https://www.pharmaradar360.com/article/tiziana-life-sciences-files-for-orphan-drug-designation-with-the-fda-for-intrana-8592ad3e96be52ebPharmaRadar360en2026-09-30T11:00:00.000ZTiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)https://www.pharmaradar360.com/article/celea-therapeutics-presents-surpass-ipf-phase-3-trial-design-and-statistical-con-1500bb7df53436e9PharmaRadar360en2026-09-30T11:00:00.000ZCelea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026https://www.pharmaradar360.com/article/b2cfd5079444a08fPharmaRadar360en2026-09-30T10:53:21.000ZΕπίσκεψη του Προέδρου του ΕΟΦ στον Οργανισμό Φαρμάκων της Πολωνίαςhttps://www.pharmaradar360.com/article/germany-s-pharma-industry-enters-a-new-investment-phase-as-biotech-and-innovatio-037df9864ddfd250PharmaRadar360en2026-09-30T10:52:44.000ZGermany's Pharma Industry Enters a New Investment Phase as Biotech and Innovation Gain Momentum: Expert View by Spherical Insightshttps://www.pharmaradar360.com/article/u-s-pharmaceutical-stocks-with-mrk-as-a-notable-example-offer-greater-upside-pot-893ec7e14141d813PharmaRadar360en2026-09-30T10:30:43.000ZU.S. Pharmaceutical stocks, with MRK as a notable example, offer greater upside potential than AI stocks whose long-term prospects remain uncertain.https://www.pharmaradar360.com/article/biotech-open-platform-inaugurates-20m-industrial-biotechnology-facility-in-franc-712f54c7a02e8e34PharmaRadar360en2026-09-30T10:30:36.000ZBiotech Open Platform inaugurates €20m industrial biotechnology facility in Francehttps://www.pharmaradar360.com/article/the-biotech-reckoning-is-here-85406ed0a81c897cPharmaRadar360en2026-09-30T10:25:09.000ZThe biotech reckoning is herehttps://www.pharmaradar360.com/article/pittsburgh-biotech-partners-with-boston-area-company-forming-new-startup-4a12fb92a37058e5PharmaRadar360en2026-09-30T10:24:28.000ZPittsburgh biotech partners with Boston-area company, forming new startuphttps://www.pharmaradar360.com/article/ortet-launches-with-500-million-commitment-for-healthcare-ai-dc22c7f885ebff8cPharmaRadar360en2026-09-30T10:22:11.000ZOrtet launches with $500 million commitment for healthcare AIhttps://www.pharmaradar360.com/article/about-115-million-from-a-share-sale-is-expected-to-help-fund-sagimet-s-acne-tria-9d858763166cf7ffPharmaRadar360en2026-09-30T10:19:00.000ZAbout $115 million from a share sale is expected to help fund Sagimet's acne trial and other drug work.https://www.pharmaradar360.com/article/sagimet-biosciences-reports-positive-52-week-phase-3-ole-results-for-denifanstat-cc0a936d71445572PharmaRadar360en2026-09-30T10:10:00.000ZSagimet Biosciences Reports Positive 52-Week Phase 3 OLE Results for Denifanstat in Moderate to Severe Acnehttps://www.pharmaradar360.com/article/lilly-reports-retatrutide-weight-and-blood-sugar-milestones-at-easd-0bd6fc31348746afPharmaRadar360en2026-09-30T09:58:20.000ZLilly reports retatrutide weight and blood sugar milestones at EASDhttps://www.pharmaradar360.com/article/kodiak-targets-zenkuda-filing-after-two-drugs-pass-wet-amd-trial-594e0cf4f8388431PharmaRadar360en2026-09-30T09:58:20.000ZKodiak targets Zenkuda filing after two drugs pass wet AMD trialhttps://www.pharmaradar360.com/article/abbvie-presents-detailed-phase-1-data-for-abbv-295-a-long-acting-amylin-analog-d-ba648235dd26ba26PharmaRadar360en2026-09-30T09:45:00.000ZAbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026https://www.pharmaradar360.com/article/hepatitis-a-b-vaccine-patient-group-direction-template-c64fed735e022261PharmaRadar360en2026-09-30T09:44:16.000ZHepatitis A/B vaccine: patient group direction templatehttps://www.pharmaradar360.com/article/hepatitis-a-vaccine-patient-group-direction-pgd-template-4ddfa9d8b07f8506PharmaRadar360en2026-09-30T09:43:37.000ZHepatitis A vaccine: patient group direction (PGD) templatehttps://www.pharmaradar360.com/article/fda-fines-six-five-star-hotels-for-food-safety-issues-550720fc5facea2bPharmaRadar360en2026-09-30T09:36:19.000ZFDA fines six five-star hotels for food safety issueshttps://www.pharmaradar360.com/article/a-month-inside-europe-s-medicine-review-process-83fc266b5b436803PharmaRadar360en2026-09-30T09:34:43.000ZA month inside Europe’s medicine review processhttps://www.pharmaradar360.com/article/c-t-e-can-t-be-detected-in-the-living-new-brain-research-offers-hope-1041ed373aa9d61cPharmaRadar360en2026-09-30T09:17:57.000ZC.T.E. Can’t Be Detected in the Living. New Brain Research Offers Hope.https://www.pharmaradar360.com/article/active-biotech-says-japan-grants-patent-for-laquinimod-ophthalmic-formulation-0a8b9d95023bb688PharmaRadar360en2026-09-30T09:06:09.000ZActive Biotech Says Japan Grants Patent For Laquinimod Ophthalmic Formulationhttps://www.pharmaradar360.com/article/toward-a-new-era-of-pharmaceutical-education-tupls-and-transcosmos-launch-a-co-d-1748930ac01b2527PharmaRadar360en2026-09-30T09:05:00.000ZToward a new era of pharmaceutical education: TUPLS and transcosmos launch a co-development project to build an AI-powered, dialogue-based learning platformhttps://www.pharmaradar360.com/article/active-biotech-granted-patent-for-laquinimod-in-japan-bf8fb4cd351ae068PharmaRadar360en2026-09-30T09:01:22.000ZActive Biotech Granted Patent for Laquinimod in Japanhttps://www.pharmaradar360.com/article/sphr-trainee-jennie-parnham-wins-nihr-impact-award-48211b8e1600ebd2PharmaRadar360en2026-09-30T08:59:21.000ZSPHR trainee Jennie Parnham wins NIHR Impact Awardhttps://www.pharmaradar360.com/article/novo-holdings-ups-its-bet-on-swedish-heart-drug-developer-anacardio-e6a6e494b6e93c2ePharmaRadar360en2026-09-30T08:58:01.000ZNovo Holdings ups its bet on Swedish heart drug developer Anacardiohttps://www.pharmaradar360.com/article/miracle-fda-approved-weight-loss-drug-postponed-to-2022-2bcd4b4d90ba164ePharmaRadar360en2026-09-30T08:50:15.000Zmiracle fda approved weight loss drug postponed to 2022https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-nyse-teva-receives-average-rating-of-moderate-c147da0d6ff96e0bPharmaRadar360en2026-09-30T08:39:15.000ZTeva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Moderate Buy" from Analystshttps://www.pharmaradar360.com/article/unicycive-therapeutics-announces-resubmission-of-new-drug-application-for-oxylan-4df6da67ccfa751ePharmaRadar360en2026-09-30T08:32:38.000ZUnicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonatehttps://www.pharmaradar360.com/article/america-s-biotech-race-with-china-must-be-won-at-home-6092e5e5c95d649aPharmaRadar360en2026-09-30T08:31:33.000ZAmerica’s biotech race with China must be won at homehttps://www.pharmaradar360.com/article/generalised-uk-habit-data-for-use-in-radiological-impact-assessments-278aebbc3c54827aPharmaRadar360en2026-09-30T08:30:01.000ZGeneralised UK habit data for use in radiological impact assessmentshttps://www.pharmaradar360.com/article/five-reputable-capsule-filling-machine-manufacturers-in-china-2026-advancing-pha-01ebb698306b5d50PharmaRadar360en2026-09-30T08:28:00.000ZFive Reputable Capsule Filling Machine Manufacturers in China 2026: Advancing Pharmaceutical Manufacturinghttps://www.pharmaradar360.com/article/transparency-data-medicines-and-healthcare-products-regulatory-agency-gpc-spendi-258a08643228ab74PharmaRadar360en2026-09-30T08:22:20.000ZTransparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2026-27https://www.pharmaradar360.com/article/guidance-magnetic-resonance-imaging-equipment-in-clinical-use-safety-guidelines-3689bc274d1035ccPharmaRadar360en2026-09-30T08:14:25.000ZGuidance: Magnetic resonance imaging equipment in clinical use: safety guidelineshttps://www.pharmaradar360.com/article/danish-biotech-breye-raises-eur-67-5m-for-eye-pill-derived-from-zealand-pharma-a53204fdb5a723b3PharmaRadar360en2026-09-30T08:08:55.000ZDanish biotech Breye raises EUR 67.5m for eye pill derived from Zealand Pharmahttps://www.pharmaradar360.com/article/leads-to-development-joins-clarenta-group-strengthening-early-stage-drug-develop-7409b17e8e163da9PharmaRadar360en2026-09-30T08:07:11.000ZLeads To Development Joins Clarenta Group, Strengthening Early-Stage Drug Development Expertise | Corporatehttps://www.pharmaradar360.com/article/top-10-bio-pharmaceutical-companies-47b4e430d6280a54PharmaRadar360en2026-09-30T08:03:59.000ZTop 10: Bio-Pharmaceutical Companieshttps://www.pharmaradar360.com/article/europe-s-biotech-frontier-new-erc-report-charts-breakthrough-potential-and-barri-c7cbecc09ef2b72ePharmaRadar360en2026-09-30T08:03:06.000ZEurope’s biotech frontier: New ERC report charts breakthrough potential and barriers |ERChttps://www.pharmaradar360.com/article/tepkinly-0cceb931baa4cd62PharmaRadar360en2026-09-30T08:01:25.000ZTepkinlyhttps://www.pharmaradar360.com/article/boletin-del-comite-de-medicamentos-de-uso-humano-julio-de-2026-d63a636c07bc3df2PharmaRadar360en2026-09-30T07:58:07.000ZBoletín del Comité de Medicamentos de Uso Humano. Julio de 2026https://www.pharmaradar360.com/article/draft-for-comments-modes-of-regulatory-inspection-for-food-and-drug-administrati-b4abf8e620774410PharmaRadar360en2026-09-30T07:43:22.000ZDraft for Comments || Modes of Regulatory Inspection for Food and Drug Administration Regulated Health Product Establishmentshttps://www.pharmaradar360.com/article/lundbeck-seeks-to-acquire-us-pharma-company-xeris-media-says-ebc5e643313b5e09PharmaRadar360en2026-09-30T07:36:19.000ZLundbeck seeks to acquire US pharma company Xeris, media sayshttps://www.pharmaradar360.com/article/nex-i-valuation-hinges-on-follow-up-licensing-deals-after-ono-agreement-78a3c455d407e629PharmaRadar360en2026-09-30T07:35:57.000ZNEX-I valuation hinges on follow-up licensing deals after Ono agreementhttps://www.pharmaradar360.com/article/onconic-therapeutics-doses-first-patient-in-china-phase-3-for-zacubo-injectable-7b633b568214b5f9PharmaRadar360en2026-09-30T07:35:30.000ZOnconic Therapeutics doses first patient in China Phase 3 for ‘Zacubo’ injectable, adds USD 1 million milestonehttps://www.pharmaradar360.com/article/fda-approved-weight-loss-drug-2023-74921e8e571fa7a4PharmaRadar360en2026-09-30T07:23:34.000Zfda approved weight loss drug 2023https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-enters-voluntary-administration-after-phase-3-setbac-b0e19d61a3aa71f8PharmaRadar360en2026-09-30T07:14:24.000ZParadigm Biopharmaceuticals enters voluntary administration after Phase 3 setbackhttps://www.pharmaradar360.com/article/korea-breaks-ground-on-boston-style-biotech-hub-2cc3fcb1e618aaa0PharmaRadar360en2026-09-30T06:51:41.000ZKorea breaks ground on Boston-style biotech hubhttps://www.pharmaradar360.com/article/topline-results-from-the-final-analysis-of-the-phase-1-study-in-europe-on-a-nove-45a11adff0d4c771PharmaRadar360en2026-09-30T06:30:00.000ZTopline Results from the Final Analysis of the Phase 1 Study in Europe on a Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546)https://www.pharmaradar360.com/article/c868404aea8cb29aPharmaRadar360en2026-09-30T06:30:00.000Z韓国における子会社設立に関するお知らせhttps://www.pharmaradar360.com/article/establishment-of-a-subsidiary-in-south-korea-54237f070f4c63dfPharmaRadar360en2026-09-30T06:30:00.000ZEstablishment of a Subsidiary in South Koreahttps://www.pharmaradar360.com/article/biotech-open-platform-danone-michelin-co-open-20m-precision-fermentation-facilit-340745b08f1129dePharmaRadar360en2026-09-30T06:14:33.000ZBiotech Open Platform: Danone, Michelin & Co Open €20M Precision Fermentation Facilityhttps://www.pharmaradar360.com/article/interim-results-for-the-six-months-to-june-30-2026-and-business-update-29eb3af4f3a7178aPharmaRadar360en2026-09-30T06:08:29.000ZInterim Results for the Six Months to June 30, 2026, and Business Updatehttps://www.pharmaradar360.com/article/lifordi-ceo-arthur-tzianabos-identifies-cmc-as-a-critical-factor-in-biotech-prod-1cf2369d55cea83bPharmaRadar360en2026-09-30T05:41:32.000ZLifordi CEO Arthur Tzianabos Identifies CMC as a Critical Factor in Biotech Product Developmenthttps://www.pharmaradar360.com/article/2-indians-charged-with-selling-fake-ozempic-in-us-6b96ed5306402f8dPharmaRadar360en2026-09-30T05:39:31.000Z2 Indians charged with selling fake Ozempic in UShttps://www.pharmaradar360.com/article/abbvie-highlights-positive-results-from-the-phase-2-apex-part-b-study-of-zumilok-7ed1e7c190da1b9cPharmaRadar360en2026-09-30T05:30:00.000ZAbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026https://www.pharmaradar360.com/article/12-000-inspections-875-arrests-603-licences-suspended-maharashtra-fda-chief-tuka-2500cfdfef4116e8PharmaRadar360en2026-09-30T05:25:00.000Z12,000 inspections, 875 arrests, 603 licences suspended: Maharashtra FDA chief Tukaram Mundhe on 3-monthttps://www.pharmaradar360.com/article/roche-s-fenebrutinib-is-the-first-btk-inhibitor-to-receive-u-s-fda-filing-accept-0f77dcb44e870cc0PharmaRadar360en2026-09-30T05:00:00.000ZRoche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosishttps://www.pharmaradar360.com/article/abbvie-showcases-leadership-in-dermatology-research-with-new-clinical-and-real-w-45bf842d8f163d49PharmaRadar360en2026-09-30T05:00:00.000ZAbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congresshttps://www.pharmaradar360.com/article/total-revenue-of-rtw-biotech-opportunities-ltd-usd-han-0bm-3b93c608ff7c8517PharmaRadar360en2026-09-30T04:34:40.000ZTotal revenue of RTW Biotech Opportunities Ltd USD – HAN:0BMhttps://www.pharmaradar360.com/article/biotech-lagged-the-broader-market-in-september-did-retail-favorites-sls-ibrx-vnd-76ffa8390f469760PharmaRadar360en2026-09-30T03:47:00.000ZBiotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?https://www.pharmaradar360.com/article/hutchmed-astrazeneca-submit-lung-cancer-drug-application-for-orpathys-tagrisso-c-c80bf797e79598cfPharmaRadar360en2026-09-30T03:25:00.000ZHutchmed, AstraZeneca Submit Lung Cancer Drug Application for ORPATHYS-TAGRISSO Combination to U.S. FDAhttps://www.pharmaradar360.com/article/why-is-cspc-pharmaceutical-stock-surging-today-d6a116a3bdf8a511PharmaRadar360en2026-09-30T03:09:15.000ZWhy is CSPC Pharmaceutical stock surging today?https://www.pharmaradar360.com/article/ibento-ibento-report-of-pmda-atc-generic-drugs-review-seminar-2026-ddebe5b20a582c71PharmaRadar360en2026-09-30T03:00:00.000Z[IBENTO][IBENTO]Report of PMDA-ATC Generic Drugs Review Seminar 2026https://www.pharmaradar360.com/article/anzen-mhlw-pharmaceuticals-and-medical-devices-safety-information-no-431-posted-50b3f286a95a4ea1PharmaRadar360en2026-09-30T03:00:00.000Z[ANZEN]MHLW Pharmaceuticals and Medical Devices Safety Information No.431 postedhttps://www.pharmaradar360.com/article/shinsa-consultations-updated-a4b6e68d1bde6e77PharmaRadar360en2026-09-30T03:00:00.000Z[SHINSA]"Consultations" Updatedhttps://www.pharmaradar360.com/article/kokusai-pmda-updates-2026-no-3-posted-632dcaa22308e81cPharmaRadar360en2026-09-30T03:00:00.000Z[KOKUSAI]PMDA Updates (2026 No.3) postedhttps://www.pharmaradar360.com/article/kokusai-for-industry-for-development-in-japan-updated-f53b61917a315f64PharmaRadar360en2026-09-30T03:00:00.000Z[KOKUSAI]“For Industry - for development in Japan “ Updated.https://www.pharmaradar360.com/article/glp-1-payment-risks-what-pharmacies-should-review-with-their-processor-f1ec0ea7ba435cccPharmaRadar360en2026-09-30T02:44:37.000ZGLP-1 Payment Risks: What Pharmacies Should Review with Their Processorhttps://www.pharmaradar360.com/article/free-float-of-rtw-biotech-opportunities-ltd-usd-han-0bm-868f29e70aa88dbbPharmaRadar360en2026-09-30T02:17:35.000ZFree float of RTW Biotech Opportunities Ltd USD – HAN:0BMhttps://www.pharmaradar360.com/article/neoimmunetech-partner-adds-il-33-antibody-plans-financing-announcement-for-nt-i7-4785723b07887e1bPharmaRadar360en2026-09-30T02:03:51.000ZNeoImmuneTech partner adds IL-33 antibody, plans financing announcement for NT-I7 trialshttps://www.pharmaradar360.com/article/2022-weight-loss-drug-0b9a3e653e8333f6PharmaRadar360en2026-09-30T01:54:07.000Z2022 weight loss drughttps://www.pharmaradar360.com/article/capex-per-share-of-rtw-biotech-opportunities-ltd-usd-han-0bm-47f499b89dc53c3dPharmaRadar360en2026-09-30T01:28:19.000ZCapEx per share of RTW Biotech Opportunities Ltd USD – HAN:0BMhttps://www.pharmaradar360.com/article/former-republican-congressional-leader-new-phrma-ceo-washington-dc-s-powerful-ph-dabbfa132ad8788ePharmaRadar360en2026-09-30T01:23:34.000ZFormer Republican congressional leader, new PhRMA CEO, Washington, DC’s powerful pharmaceutical lobbyhttps://www.pharmaradar360.com/article/net-current-asset-value-per-share-of-rtw-biotech-opportunities-ltd-usd-han-0bm-69019e1097838337PharmaRadar360en2026-09-30T01:22:32.000ZNet current asset value per share of RTW Biotech Opportunities Ltd USD – HAN:0BMhttps://www.pharmaradar360.com/article/return-on-invested-capital-of-rtw-biotech-opportunities-ltd-usd-han-0bm-3a00b162c678a55cPharmaRadar360en2026-09-30T01:10:19.000ZReturn on invested capital % of RTW Biotech Opportunities Ltd USD – HAN:0BMhttps://www.pharmaradar360.com/article/pharmaceutical-impurity-synthesis-and-isolation-services-report-capitalize-on-a-f451a624e9dd31b1PharmaRadar360en2026-09-30T01:02:50.000ZPharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles Riverhttps://www.pharmaradar360.com/article/return-on-equity-of-rtw-biotech-opportunities-ltd-usd-han-0bm-5c4a17323fb317bePharmaRadar360en2026-09-30T00:17:30.000ZReturn on equity % of RTW Biotech Opportunities Ltd USD – HAN:0BMhttps://www.pharmaradar360.com/article/fda-withdraws-publication-of-covid-shingles-vaccine-research-findings-0c9137b444e2e92aPharmaRadar360en2026-09-30T00:09:17.000ZFDA withdraws publication of COVID, shingles vaccine research findingshttps://www.pharmaradar360.com/article/net-margin-of-rtw-biotech-opportunities-ltd-usd-han-0bm-bf0a69586d624702PharmaRadar360en2026-09-30T00:03:56.000ZNet margin % of RTW Biotech Opportunities Ltd USD – HAN:0BMhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-a827cc8f22a40fcbPharmaRadar360en2026-09-30T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-3fe2b10080badceePharmaRadar360en2026-09-30T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-47d2420ee9851c1cPharmaRadar360en2026-09-30T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-8bc40ef4e3d7c0fcPharmaRadar360en2026-09-30T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-65af6f8af4fccc35PharmaRadar360en2026-09-30T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-4b618c60869cae24PharmaRadar360en2026-09-30T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-ebfa8ed2e7fb945aPharmaRadar360en2026-09-30T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-4bc2c33947801ce2PharmaRadar360en2026-09-30T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-2160dab2e7e3c6b1PharmaRadar360en2026-09-30T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-87b5c2e46f260b27PharmaRadar360en2026-09-30T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-914106cdcacf29f5PharmaRadar360en2026-09-30T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-0596637f248d9b3bPharmaRadar360en2026-09-30T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-03fa992fcc673de1PharmaRadar360en2026-09-30T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-281e9b92b549c99bPharmaRadar360en2026-09-30T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medical-devices-gastroenterology-urology-devices-classification-of-the-flushing-2241d88bc288fe54PharmaRadar360en2026-09-30T00:00:00.000ZMedical Devices; Gastroenterology-Urology Devices; Classification of the Flushing and Storage Solution for Vascular Autografts at Room Temperaturehttps://www.pharmaradar360.com/article/medicare-program-fy-2027-hospice-wage-index-and-payment-rate-update-and-hospice-d4ece58ae83b3797PharmaRadar360en2026-09-30T00:00:00.000ZMedicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements; Correctionhttps://www.pharmaradar360.com/article/national-institute-of-neurological-disorders-and-stroke-notice-of-closed-meeting-3ec6cafaed143079PharmaRadar360en2026-09-30T00:00:00.000ZNational Institute of Neurological Disorders and Stroke; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-4af4c9ecdeb95d8aPharmaRadar360en2026-09-30T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-bb00b4b7a07d98b3PharmaRadar360en2026-09-30T00:00:00.000ZCenter For Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/recharter-for-the-council-on-graduate-medical-education-8c1220b216214b75PharmaRadar360en2026-09-30T00:00:00.000ZRecharter for the Council on Graduate Medical Educationhttps://www.pharmaradar360.com/article/current-list-of-hhs-certified-laboratories-and-instrumented-initial-testing-faci-7dd99f5a2282d5b2PharmaRadar360en2026-09-30T00:00:00.000ZCurrent List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencieshttps://www.pharmaradar360.com/article/determination-that-isturisa-osilodrostat-tablets-10-milligrams-was-not-withdrawn-6de49f7542dc18a2PharmaRadar360en2026-09-30T00:00:00.000ZDetermination That ISTURISA (Osilodrostat) Tablets, 10 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/medicare-program-prospective-payment-system-and-consolidated-billing-for-skilled-01c9b65e5b37d438PharmaRadar360en2026-09-30T00:00:00.000ZMedicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 2027; Correctionhttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-5605bfb4b4dbc935PharmaRadar360en2026-09-30T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/notice-of-supplemental-award-maternal-health-research-collaborative-for-minority-f5dd773dd1d3e606PharmaRadar360en2026-09-30T00:00:00.000ZNotice of Supplemental Award; Maternal Health Research Collaborative for Minority-Serving Institutions Coordinatinghttps://www.pharmaradar360.com/article/autism-longitudinal-data-project-and-linking-the-boston-birth-cohort-and-pregnan-e47c048c36109770PharmaRadar360en2026-09-30T00:00:00.000ZAutism Longitudinal Data Project and Linking the Boston Birth Cohort and Pregnancy to Early Life Longitudinal Data System and Community-Level Health Databases: A Longitudinal Cohort of Mother-Child Dyadshttps://www.pharmaradar360.com/article/drug-label-update-unspecified-product-b49f3df76b743828PharmaRadar360en2026-09-30T00:00:00.000ZDrug label update: unspecified producthttps://www.pharmaradar360.com/article/watch-bernstein-s-liang-on-china-s-biotech-stock-rally-221d81d95bf0d160PharmaRadar360en2026-09-30T00:00:00.000ZWatch Bernstein's Liang on China's Biotech Stock Rallyhttps://www.pharmaradar360.com/article/korean-medication-algorithm-project-for-bipolar-disorder-2026-comparisons-with-o-bf3365f4954171bfPharmaRadar360en2026-09-30T00:00:00.000ZKorean Medication Algorithm Project for Bipolar Disorder 2026: Comparisons with Other Treatment Guidelineshttps://www.pharmaradar360.com/article/clinical-significance-of-thymus-serpyllum-l-essential-oil-in-patients-with-synco-e208ab75d09f5817PharmaRadar360en2026-09-30T00:00:00.000ZCLINICAL SIGNIFICANCE OF THYMUS SERPYLLUM L. ESSENTIAL OIL IN PATIENTS WITH SYNCOPEhttps://www.pharmaradar360.com/article/sex-specific-efficacy-and-safety-of-potassium-competitive-acid-blocker-bismuth-q-a8b82c8524880673PharmaRadar360en2026-09-30T00:00:00.000ZSex-Specific Efficacy and Safety of Potassium-Competitive Acid Blocker–Bismuth Quadruple Therapy for Second-Line <i>Helicobacter pylori</i> Eradication: An Open-Label Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-and-functional-outcome-of-anterior-cruciate-ligament-reconstruction-wit-a5e6c3c3ce00caafPharmaRadar360en2026-09-30T00:00:00.000ZClinical and Functional Outcome of Anterior Cruciate Ligament Reconstruction with Hamstring Autograft: a Comparison study of All-Inside versus Complete Tibial Tunnel Techniqueshttps://www.pharmaradar360.com/article/diet-intervention-in-obese-patients-a-retrospective-study-e0b8a335aa6de9e6PharmaRadar360en2026-09-30T00:00:00.000ZDiet Intervention in Obese Patients: A Retrospective Studyhttps://www.pharmaradar360.com/article/a-simple-model-for-a-complex-procedure-broadening-access-to-endoscopic-retrograd-13c4a722b0e36a00PharmaRadar360en2026-09-30T00:00:00.000ZA simple model for a complex procedure: broadening access to endoscopic retrograde cholangiopancreatography simulationhttps://www.pharmaradar360.com/article/hybrid-endoscopic-submucosal-dissection-enhances-efficiency-with-comparable-cura-59f35ebeba6339bcPharmaRadar360en2026-09-30T00:00:00.000ZHybrid endoscopic submucosal dissection enhances efficiency with comparable curative outcomes: a Bayesian meta-analysis, systematic review, and Monte Carlo simulation of randomized controlled trialshttps://www.pharmaradar360.com/article/rare-complication-of-plastic-endoscopic-retrograde-biliary-drainage-stent-placem-34aa435d061aaeb3PharmaRadar360en2026-09-30T00:00:00.000ZRare complication of plastic endoscopic retrograde biliary drainage stent placement: bile duct perforationhttps://www.pharmaradar360.com/article/advanced-endoscopy-and-artificial-intelligence-enabled-vascular-healing-for-ulce-6f5b22e6f93bc589PharmaRadar360en2026-09-30T00:00:00.000ZAdvanced endoscopy and artificial intelligence-enabled vascular healing for ulcerative colitis: promising frontiers or mere mirage?https://www.pharmaradar360.com/article/tirzepatide-for-obesity-related-obstructive-sleep-apnea-beyond-weight-loss-towar-226cbd5877915645PharmaRadar360en2026-09-30T00:00:00.000ZTirzepatide for Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Reductions in Hypoxic Burden and Cardiometabolic Risk Markershttps://www.pharmaradar360.com/article/secondary-immunodeficiencies-clinical-immunology-for-infectious-disease-speciali-1961baac8879a32fPharmaRadar360en2026-09-30T00:00:00.000ZSecondary Immunodeficiencies: Clinical Immunology for Infectious Disease Specialistshttps://www.pharmaradar360.com/article/clinical-outcomes-of-antegrade-double-j-stent-placement-in-patients-with-failed-7d033cbbf6555fe5PharmaRadar360en2026-09-30T00:00:00.000ZClinical Outcomes of Antegrade Double-J Stent Placement in Patients with Failed Retrograde Ureteral Stentinghttps://www.pharmaradar360.com/article/computational-prioritization-of-novel-nabumetone-derived-heterocycles-as-potenti-01e05982e70ec902PharmaRadar360en2026-09-30T00:00:00.000ZComputational Prioritization of Novel Nabumetone-Derived Heterocycles as Potential Cyclooxygenase-2 Inhibitorshttps://www.pharmaradar360.com/article/building-happier-healthier-villages-a-process-evaluation-of-sri-lanka-s-happy-vi-4623b351e407ffd9PharmaRadar360en2026-09-30T00:00:00.000ZBuilding happier, healthier villages: a process evaluation of Sri Lanka’s Happy Village projecthttps://www.pharmaradar360.com/article/analysis-of-active-components-and-high-performance-liquid-chromatography-hplc-pr-acfaf9e59062dde5PharmaRadar360en2026-09-30T00:00:00.000ZAnalysis of Active Components and High-Performance Liquid Chromatography (HPLC) Profiling of Emperor Scorpion (Pandinus imperator) against Selected Bacterial Strainshttps://www.pharmaradar360.com/article/clinical-evaluation-and-treatment-of-obesity-in-women-across-selected-life-stage-3e72df3b533d85f2PharmaRadar360en2026-09-30T00:00:00.000ZClinical evaluation and treatment of obesity in women across selected life stages: a narrative reviewhttps://www.pharmaradar360.com/article/hyaluronic-acid-molecular-weight-in-the-minimally-invasive-management-of-temporo-5f374be1c1c29aa2PharmaRadar360en2026-09-30T00:00:00.000ZHyaluronic Acid Molecular Weight in the Minimally Invasive Management of Temporomandibular Disorders: A Scoping Reviewhttps://www.pharmaradar360.com/article/analysis-of-treatment-patterns-and-outcomes-among-patients-with-third-line-or-la-0b6ff6a935641b5dPharmaRadar360en2026-09-30T00:00:00.000ZAnalysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United Stateshttps://www.pharmaradar360.com/article/is-fibromyalgia-overlooked-in-cases-of-idiopathic-granulomatous-mastitis-a-cross-f5a224c91743e545PharmaRadar360en2026-09-30T00:00:00.000ZIs Fibromyalgia Overlooked in Cases of Idiopathic Granulomatous Mastitis? A Cross-Sectional Controlled Studyhttps://www.pharmaradar360.com/article/staging-and-grading-advanced-periodontitis-with-large-language-models-from-stand-bb5841acb2be202dPharmaRadar360en2026-09-30T00:00:00.000ZStaging and Grading Advanced Periodontitis with Large Language Models from Standardized Case Summaries: A Multicenter Concordance and Reproducibility Studyhttps://www.pharmaradar360.com/article/comparative-effects-of-acute-hiie-and-mice-on-executive-function-prefrontal-oxyh-989c6271a1726054PharmaRadar360en2026-09-30T00:00:00.000ZComparative Effects of Acute HIIE and MICE on Executive Function, Prefrontal Oxyhaemoglobin Responses, and Related Biomarkers in Sedentary Young Adults: A Randomized Crossover Trialhttps://www.pharmaradar360.com/article/18f-fdg-pet-ct-metabolic-patterns-and-clinical-parameters-correlate-with-disease-3afbeab833ac3432PharmaRadar360en2026-09-30T00:00:00.000Z18F-FDG PET/CT metabolic patterns and clinical parameters correlate with disease severity in autoimmune encephalitishttps://www.pharmaradar360.com/article/case-report-relapse-of-sle-associated-with-ebv-infection-in-a-patient-after-car-237371e34e6fbc76PharmaRadar360en2026-09-30T00:00:00.000ZCase Report: Relapse of SLE associated with EBV infection in a patient after CAR-T cell therapy: a clinical casehttps://www.pharmaradar360.com/article/cardiovascular-and-mortality-outcomes-with-jak-versus-tnf-inhibitors-in-rheumato-29a14d58cb00c74cPharmaRadar360en2026-09-30T00:00:00.000ZCardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA)https://www.pharmaradar360.com/article/thoracic-metastasis-in-ovarian-cancer-clinical-characteristics-ca-125-levels-and-2de6e8e8ccb506f0PharmaRadar360en2026-09-30T00:00:00.000ZThoracic Metastasis in Ovarian Cancer: Clinical Characteristics, CA-125 Levels, and Pleural Fluid Findings in a 3-Year Retrospective Studyhttps://www.pharmaradar360.com/article/review-of-bioelectrical-impedance-devices-in-clinical-and-oncological-nutrition-eb5abda62bff0dc3PharmaRadar360en2026-09-30T00:00:00.000ZReview of: "Bioelectrical Impedance Devices in Clinical and Oncological Nutrition: Types, Physical Principles, and Integration with Biochemical and Pathological Biomarkers"https://www.pharmaradar360.com/article/effectiveness-of-personalized-rehabilitation-functional-electrical-stimulation-a-9628ac7f2751ec78PharmaRadar360en2026-09-30T00:00:00.000ZEFFECTIVENESS OF PERSONALIZED REHABILITATION, FUNCTIONAL ELECTRICAL STIMULATION, AND COGNITIVE-MOTOR TRAINING ON MOTOR FUNCTION AND COGNITIVE RECOVERY IN STROKE PATIENTS: A RANDOMIZED CONTROLLED TRIALhttps://www.pharmaradar360.com/article/methotrexate-folate-interplay-from-pharmacological-mechanisms-to-clinical-toxici-22ea2f04f17c345ePharmaRadar360en2026-09-30T00:00:00.000ZMETHOTREXATE-FOLATE INTERPLAY: FROM PHARMACOLOGICAL MECHANISMS TO CLINICAL TOXICITY MANAGEMENThttps://www.pharmaradar360.com/article/gastrointestinal-parasites-of-duck-cairina-moschata-reared-at-the-experimental-f-d70fd73eb751bb35PharmaRadar360en2026-09-30T00:00:00.000ZGASTROINTESTINAL PARASITES OF DUCK (Cairina moschata) REARED AT THE EXPERIMENTAL FARM OF THE CENTER FOR RESEARCH IN ECOLOGY, ABIDJAN, CÔTE D'IVOIREhttps://www.pharmaradar360.com/article/inhibitory-efficacy-of-the-hydroalcoholic-extract-of-ficus-iteophylla-miq-morace-b0194be700f5b4c5PharmaRadar360en2026-09-30T00:00:00.000ZINHIBITORY EFFICACY OF THE HYDROALCOHOLIC EXTRACT OF FICUS ITEOPHYLLA MIQ. (MORACEAE) LEAVES AGAINST CLINICAL STRAINS OF MULTIDRUG-RESISTANT PSEUDOMONAShttps://www.pharmaradar360.com/article/characterization-of-human-mesenchymal-stem-cell-according-to-delivery-route-and-966a5a72762014a4PharmaRadar360en2026-09-30T00:00:00.000ZCharacterization of human mesenchymal stem cell according to delivery route and its correlation with clinical-gynecological historyhttps://www.pharmaradar360.com/article/clinical-effect-analysis-of-different-treatment-schemes-for-children-with-ulnar-cff6d953f2ae9a29PharmaRadar360en2026-09-30T00:00:00.000ZClinical effect analysis of different treatment schemes for children with ulnar and radial double fractureshttps://www.pharmaradar360.com/article/prevalence-causes-and-clinical-course-of-patients-with-surgical-reintervention-d-7e03a0abd6329ea1PharmaRadar360en2026-09-30T00:00:00.000ZPrevalence, causes, and clinical course of patients with surgical reintervention due to complications during cesarean sectionhttps://www.pharmaradar360.com/article/treatment-and-outcome-in-12-cases-of-olfactory-neuroblastoma-at-mexico-s-nationa-7552f4a69675294ePharmaRadar360en2026-09-30T00:00:00.000ZTreatment and outcome in 12 cases of olfactory neuroblastoma at Mexico´s National Cancer Institute: A retrospective clinical analysis and literature reviewhttps://www.pharmaradar360.com/article/electrochemical-analysis-highly-selective-determination-of-tenoxicam-in-pharmace-18c25954181c4dfcPharmaRadar360en2026-09-30T00:00:00.000ZElectrochemical Analysis: Highly Selective Determination of Tenoxicam in Pharmaceutical and Environmental Samples Using a Molecularly Imprinted Polymer-Based Potentiometric Electrochemical Sensorhttps://www.pharmaradar360.com/article/efficacy-of-a-weighted-vest-aerobic-dance-intervention-for-enhancing-lower-extre-089572627e92cae7PharmaRadar360en2026-09-30T00:00:00.000ZEfficacy of a weighted-vest aerobic dance intervention for enhancing lower extremity strength and mobility in older adults: a randomized controlled trialhttps://www.pharmaradar360.com/article/evaluation-of-dental-amp-skeletal-effects-of-anterior-bite-plane-amp-anterior-bi-50e4e4e7c295814fPharmaRadar360en2026-09-30T00:00:00.000ZEvaluation of dental & skeletal effects of anterior bite plane & anterior bite turbo in patients with deep bite malocclusion – A randomized clinical trialhttps://www.pharmaradar360.com/article/synthesis-and-characterization-of-thermo-responsive-magnetic-molecularly-imprint-a8fd0e28e9a5f120PharmaRadar360en2026-09-30T00:00:00.000ZSynthesis And Characterization Of Thermo-responsive Magnetic Molecularly Imprinted Polymers For Selective Recognition Of Peptide-drug Conjugateshttps://www.pharmaradar360.com/article/lt-i-gt-braf-lt-i-gt-and-lt-i-gt-mek-lt-i-gt-inhibitors-in-the-treatment-of-lang-655aae601098c8fdPharmaRadar360en2026-09-30T00:00:00.000Z<i>BRAF</i>- and <i>MEK</i>-inhibitors in the treatment of Langerhans cell histiocytosis in children and adults: molecular basis, clinical experience and unresolved issueshttps://www.pharmaradar360.com/article/effect-of-handle-design-on-fatigue-development-and-resolution-in-dental-hygienis-56632e66637fd9cdPharmaRadar360en2026-09-30T00:00:00.000ZEffect of Handle Design on Fatigue Development and Resolution in Dental Hygienists: Clinical Implicationshttps://www.pharmaradar360.com/article/beyond-the-oscillometric-cuff-the-utility-of-point-of-care-ultrasound-derived-bl-c7bb62e0e5caa36fPharmaRadar360en2026-09-30T00:00:00.000ZBeyond the oscillometric cuff: the utility of point-of-care ultrasound–derived blood pressure in shockhttps://www.pharmaradar360.com/article/how-dispatchers-recognize-agonal-and-abnormal-breathing-in-suspected-cardiac-arr-8b6bb5dc9f62a865PharmaRadar360en2026-09-30T00:00:00.000ZHow dispatchers recognize agonal and abnormal breathing in suspected cardiac arrest: a scoping reviewhttps://www.pharmaradar360.com/article/associations-between-learning-tools-concentration-and-electroencephalographic-re-0766a1c7644834e5PharmaRadar360en2026-09-30T00:00:00.000ZAssociations between Learning Tools, Concentration, and Electroencephalographic Responses in University Studentshttps://www.pharmaradar360.com/article/lipemic-samples-underlying-mechanisms-analytical-challenges-and-management-a041f306201070cbPharmaRadar360en2026-09-30T00:00:00.000ZLipemic Samples: Underlying Mechanisms, Analytical Challenges, and Managementhttps://www.pharmaradar360.com/article/testing-the-external-validity-of-the-standard-vs-extended-lymphadenectomy-for-mu-aacd91d39cc34bfaPharmaRadar360en2026-09-30T00:00:00.000ZTesting the external validity of the standard vs. extended lymphadenectomy for muscle invasive bladder cancer trial in a north American cohorthttps://www.pharmaradar360.com/article/exploratory-evaluation-of-dental-unit-waterline-contamination-and-red-fluorescen-8371648051ef69f0PharmaRadar360en2026-09-30T00:00:00.000ZExploratory Evaluation of Dental Unit Waterline Contamination and Red-Fluorescent Microorganisms Using QLF-D in Dental Hygiene Training Laboratorieshttps://www.pharmaradar360.com/article/changes-in-major-satisfaction-career-self-understanding-behavior-and-problem-sol-47edc75c0a664199PharmaRadar360en2026-09-30T00:00:00.000ZChanges in Major Satisfaction, Career Self-Understanding Behavior, and Problem-Solving Self-Efficacy among Dental Hygiene Students Before and After School-Based Oral Health Education Field Traininghttps://www.pharmaradar360.com/article/errata-for-biological-and-pharmaceutical-bulletin-90b1811642a66115PharmaRadar360en2026-09-30T00:00:00.000ZErrata for Biological and Pharmaceutical Bulletinhttps://www.pharmaradar360.com/article/sglt2-inhibitors-mechanisms-physiology-and-pharmacology-and-clinical-application-c4997f8c3de4d61aPharmaRadar360en2026-09-30T00:00:00.000ZSGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applicationshttps://www.pharmaradar360.com/article/from-awareness-to-moral-redemption-medicalisation-stigma-and-anti-establishment-a7c545bc8d9f43bcPharmaRadar360en2026-09-30T00:00:00.000ZFrom Awareness to Moral Redemption: Medicalisation, Stigma, and Anti-Establishment Aesthetics in the ‘Obesity Without Filters’ Spanish Campaign by Pharmaceutical Company Novo Nordiskhttps://www.pharmaradar360.com/article/extended-reality-in-endodontic-education-a-scoping-review-of-educational-impact-8f3d544fcca9021bPharmaRadar360en2026-09-30T00:00:00.000ZExtended Reality in Endodontic Education: A Scoping Review of Educational Impact, Clinical Transferability, and Future Directionshttps://www.pharmaradar360.com/article/effect-of-professional-prophylaxis-on-clinical-parameters-and-patient-comfort-ra-8df87ee1296829edPharmaRadar360en2026-09-30T00:00:00.000ZEffect of Professional Prophylaxis on Clinical Parameters and Patient Comfort: Randomized Split‐Mouth Clinical Trialhttps://www.pharmaradar360.com/article/microsurgical-vasoepididymostomy-for-epididymal-obstructive-azoospermia-microtec-546a5590ac4d2959PharmaRadar360en2026-09-30T00:00:00.000ZMicrosurgical vasoepididymostomy for epididymal obstructive azoospermia: Microtechnical evolution, clinical outcomes, reporting challenges, and a proposal for standardized outcome assessmenthttps://www.pharmaradar360.com/article/consenting-for-mortality-risk-in-dermatological-surgery-is-it-necessary-b87c9ebb71f59e67PharmaRadar360en2026-09-30T00:00:00.000ZConsenting for Mortality Risk in Dermatological Surgery: Is It Necessary?https://www.pharmaradar360.com/article/sesbania-species-a-comprehensive-review-revealing-its-medicinal-potential-throug-c35266524f330bffPharmaRadar360en2026-09-30T00:00:00.000ZSesbania species: a comprehensive review revealing its medicinal potential through phytochemical, preclinical, and clinical lenseshttps://www.pharmaradar360.com/article/methotrexate-loaded-zinc-oxide-indigo-naturalis-nanocomposite-hydrogel-attenuate-2b7f65b4c592446fPharmaRadar360en2026-09-30T00:00:00.000ZMethotrexate Loaded Zinc Oxide/Indigo naturalis Nanocomposite Hydrogel Attenuates Imiquimod-induced Psoriasis Via Suppression of Inflammation, Regulation of Apoptosis, and Inhibition of NF-κB/MAPK Signaling Pathwayshttps://www.pharmaradar360.com/article/risk-factors-for-infection-in-ndm-colonized-patients-and-applicability-of-the-gi-40958ccb728a5645PharmaRadar360en2026-09-30T00:00:00.000ZRisk factors for infection in NDM-colonized patients and applicability of the Giannella Risk Scorehttps://www.pharmaradar360.com/article/treatment-patterns-and-clinical-outcomes-among-chinese-patients-with-newly-diagn-4b1794e2fcbfbd0dPharmaRadar360en2026-09-30T00:00:00.000ZTreatment Patterns and Clinical Outcomes Among Chinese Patients With Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Study ( <scp>CHAMP</scp> ‐ <scp>MM</scp> )https://www.pharmaradar360.com/article/correction-to-inflammation-targeted-and-antioxidative-poly-ferulic-acid-nanopart-9c7fa37a28c254f6PharmaRadar360en2026-09-30T00:00:00.000ZCorrection to “Inflammation‐Targeted and Antioxidative Poly(Ferulic Acid) Nanoparticles Directly Treat Chronic Nonbacterial Prostatitis via Inhibiting Pyroptosis by Disrupting Nrf2/KEAP1 Multimer Formation and as a Robust Drug Carrier”https://www.pharmaradar360.com/article/sputum-based-test-may-identify-drug-targets-in-asthma-and-copd-patient-care-onli-66f08663128d838cPharmaRadar360en2026-09-30T00:00:00.000ZSputum-Based Test May Identify Drug Targets in Asthma and COPD – Patient Care Onlinehttps://www.pharmaradar360.com/article/pharmaceutical-testing-minimizing-supply-delays-with-packaging-compliance-labs-c-4b4d572dcde98041PharmaRadar360en2026-09-29T23:46:05.000ZPharmaceutical Testing: Minimizing Supply Delays With Packaging Compliance Labs' cGMP Facilityhttps://www.pharmaradar360.com/article/massbio-in-banker-tradesman-why-real-estate-has-to-be-part-of-biotech-s-comeback-5c696edba1bdc8ebPharmaRadar360en2026-09-29T23:01:47.000ZMassBio in Banker & Tradesman: Why Real Estate Has to Be Part of Biotech’s Comebackhttps://www.pharmaradar360.com/article/100-pharmaceutical-tariffs-go-into-effect-cce0a5d3c788690cPharmaRadar360en2026-09-29T22:39:00.000Z100% pharmaceutical tariffs go into effecthttps://www.pharmaradar360.com/article/united-states-two-indian-nationals-charged-in-connection-with-transnational-coun-a284e8b4cfcff6f3PharmaRadar360en2026-09-29T22:37:46.000ZUnited States: Two Indian Nationals Charged in Connection with Transnational Counterfeit Ozempic Schemehttps://www.pharmaradar360.com/article/supreme-court-preserves-broad-access-to-abortion-drug-mifepristone-7f64cc35a1f5e3e3PharmaRadar360en2026-09-29T22:29:38.000ZSupreme Court preserves broad access to abortion drug mifepristonehttps://www.pharmaradar360.com/article/long-term-debt-to-total-assets-ratio-of-ono-pharmaceutical-co-ltd-han-on4-1b009fe2fd1ee51dPharmaRadar360en2026-09-29T22:27:08.000ZLong term debt to total assets ratio of ONO Pharmaceutical Co., Ltd. – HAN:ON4https://www.pharmaradar360.com/article/blockbuster-retatrutide-trial-signals-a-new-high-water-mark-for-weight-loss-drug-06c25b48381b5a7dPharmaRadar360en2026-09-29T22:01:00.000ZBlockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugshttps://www.pharmaradar360.com/article/india-s-sun-pharma-plans-1-billion-local-debt-sale-for-loan-takeout-sources-say-89625efa6dacb9dcPharmaRadar360en2026-09-29T21:50:58.000ZIndia's Sun Pharma plans $1 billion local debt sale for loan takeout, sources sayhttps://www.pharmaradar360.com/article/novo-says-ozempic-shows-lower-risk-of-cardiovascular-events-compared-to-lilly-s-bb82a4c5ecbf2968PharmaRadar360en2026-09-29T21:49:58.000ZNovo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjarohttps://www.pharmaradar360.com/article/trump-administration-s-pharmaceutical-tariffs-take-effect-aecb6be7663a6c24PharmaRadar360en2026-09-29T21:49:00.000ZTrump administration's pharmaceutical tariffs take effecthttps://www.pharmaradar360.com/article/pharmaceutical-tariffs-take-effect-f53c7fb36bf42462PharmaRadar360en2026-09-29T21:47:18.000ZPharmaceutical tariffs take effecthttps://www.pharmaradar360.com/article/this-is-the-top-biotech-stock-pick-from-b-riley-securities-0bc82a245f8d6f3fPharmaRadar360en2026-09-29T21:24:17.000ZThis is the top biotech stock pick from B Riley Securitieshttps://www.pharmaradar360.com/article/78th-who-regional-committee-for-the-americas-strategy-for-strengthening-health-e-2f029a51ee343086PharmaRadar360en2026-09-29T21:19:39.000Z78th WHO Regional Committee for the Americas: Strategy for strengthening health emergency and risk management for health security 2026-2031https://www.pharmaradar360.com/article/cellbion-wins-phase-3-nod-for-prostate-cancer-drug-as-korea-rivalry-funding-loom-211e4c78ddeb51aePharmaRadar360en2026-09-29T21:01:00.000ZCellBion wins phase 3 nod for prostate cancer drug as Korea rivalry, funding loom - CHOSUNBIZhttps://www.pharmaradar360.com/article/trump-slaps-100-tariff-on-some-pharmaceutical-drugs-via-executive-order-4af25fb40b2f1154PharmaRadar360en2026-09-29T20:58:43.000ZTrump slaps 100% tariff on some pharmaceutical drugs via executive orderhttps://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558PharmaRadar360en2026-09-29T20:46:20.000ZModerna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreakhttps://www.pharmaradar360.com/article/trilink-biotechnologies-secures-additional-china-patent-for-cleancap-technology-797ebf5698316462PharmaRadar360en2026-09-29T20:33:58.000ZTriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IPhttps://www.pharmaradar360.com/article/end-of-q3-2026-biotech-updates-4e184fc759bd239fPharmaRadar360en2026-09-29T20:22:29.000ZEnd of Q3 2026 Biotech Updateshttps://www.pharmaradar360.com/article/maharashtra-fda-tightens-infant-food-norms-bans-free-samples-influencer-promotio-36899c1c0ca54de0PharmaRadar360en2026-09-29T19:52:57.000ZMaharashtra FDA tightens infant food norms, bans free samples, influencer promotionhttps://www.pharmaradar360.com/article/astrazeneca-places-a-2b-bet-on-a-summit-therapeutics-cancer-drug-9a8aafe8d0cda009PharmaRadar360en2026-09-29T19:36:53.000ZAstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drughttps://www.pharmaradar360.com/article/how-ira-negotiation-tariffs-and-mfn-converge-on-drug-prices-b8a2570c0d9721fdPharmaRadar360en2026-09-29T19:24:13.000ZHow IRA Negotiation, Tariffs and MFN Converge on Drug Priceshttps://www.pharmaradar360.com/article/weight-loss-drug-can-cut-heart-attacks-and-strokes-38c46bd16671a482PharmaRadar360en2026-09-29T19:20:54.000Zweight-loss drug can cut heart attacks and strokeshttps://www.pharmaradar360.com/article/dallas-biotech-startup-lands-2-6m-grant-to-fight-cancer-efdf0ac6a20ac32dPharmaRadar360en2026-09-29T19:08:06.000ZDallas Biotech Startup Lands $2.6M Grant to Fight Cancerhttps://www.pharmaradar360.com/article/fabrice-chouraqui-steps-down-as-ceo-of-pharming-pharmexec-710ff7bd4faed7f0PharmaRadar360en2026-09-29T18:40:43.000ZFabrice Chouraqui Steps Down as CEO of Pharming | PharmExechttps://www.pharmaradar360.com/article/sgs-webinar-to-address-fda-compliance-in-shrimp-seafood-supply-chains-bd2f19d7dc07a564PharmaRadar360en2026-09-29T18:37:00.000ZSGS Webinar to Address FDA Compliance in Shrimp, Seafood Supply Chainshttps://www.pharmaradar360.com/article/beam-therapeutics-sues-chinese-biotech-vc-backed-startup-alleging-theft-of-intel-c119ea85d22abadbPharmaRadar360en2026-09-29T18:22:00.000ZBeam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual propertyhttps://www.pharmaradar360.com/article/yaniris-silva-reflects-on-the-power-of-life-changing-opportunities-b11dbe7fa92953d0PharmaRadar360en2026-09-29T18:13:45.000ZYaniris Silva Reflects on the Power of Life-Changing Opportunitieshttps://www.pharmaradar360.com/article/beam-therapeutics-sues-chinese-biotech-vc-backed-startup-alleging-theft-of-intel-680c5abccf3d8b1fPharmaRadar360en2026-09-29T17:55:06.000ZBeam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual propertyhttps://www.pharmaradar360.com/article/anmat-levanto-la-inhibicion-de-las-actividades-productivas-de-lassen-pharma-s-a-60d77ae320f01351PharmaRadar360en2026-09-29T17:23:42.000ZANMAT levantó la inhibición de las actividades productivas de Lassen Pharma S.Ahttps://www.pharmaradar360.com/article/ima-life-completes-30m-pharmaceutical-equipment-expansion-in-western-new-york-5acf9da041b76ecfPharmaRadar360en2026-09-29T17:22:00.000ZIMA Life Completes $30M Pharmaceutical Equipment Expansion In Western New Yorkhttps://www.pharmaradar360.com/article/akeso-s-phase-3-gastric-cancer-trial-pits-cadonilimab-against-nivolumab-based-ca-7bd304d458319dadPharmaRadar360en2026-09-29T17:18:15.000ZAkeso’s Phase 3 Gastric Cancer Trial Pits Cadonilimab Against Nivolumab-Based Carehttps://www.pharmaradar360.com/article/global-phase-3-upstream-mg-trial-of-telitacicept-advances-enrollment-in-generali-685bd79fb891f9b3PharmaRadar360en2026-09-29T17:02:05.000ZGlobal Phase 3 UPSTREAM MG Trial of Telitacicept Advances Enrollment in Generalized Myasthenia Gravishttps://www.pharmaradar360.com/article/fda-concerns-unapproved-glp-1-drugs-weight-loss-retatrutide-09e6b29613908cc2PharmaRadar360en2026-09-29T16:51:54.000Zfda concerns unapproved glp-1 drugs weight loss retatrutidehttps://www.pharmaradar360.com/article/new-glp-1-drug-2b5a0deeae904086PharmaRadar360en2026-09-29T16:51:27.000Znew glp 1 drughttps://www.pharmaradar360.com/article/evaluating-zeleciment-basivarsen-in-myotonic-dystrophy-type-1-the-phase-3-harmon-b9554d6510fafdd6PharmaRadar360en2026-09-29T16:41:18.000ZEvaluating Zeleciment Basivarsen in Myotonic Dystrophy Type 1: The Phase 3 HARMONIA Trialhttps://www.pharmaradar360.com/article/new-fda-approved-weight-loss-drug-2024-4b083787d6dcaebfPharmaRadar360en2026-09-29T16:34:05.000Znew fda approved weight loss drug 2024https://www.pharmaradar360.com/article/cellbion-pocubotide-rpt-commercialization-prep-on-track-targeting-korean-phase-3-b7d5903f39ba9497PharmaRadar360en2026-09-29T16:27:49.000ZCellBion: “‘Pocubotide’ RPT commercialization prep on track, targeting Korean Phase 3 approval within Q4”https://www.pharmaradar360.com/article/ingenia-files-for-u-s-phase-1-2a-trials-for-ckd-candidate-igt-303-accelerates-li-272d292a0b399258PharmaRadar360en2026-09-29T16:27:48.000ZINGENIA files for U.S. Phase 1/2a trials for CKD candidate ‘IGT-303,’ accelerates licensing-out discussionshttps://www.pharmaradar360.com/article/thx-pharma-reports-its-financial-results-for-the-first-half-of-2026-89a9c5eb4f53f74dPharmaRadar360en2026-09-29T16:19:19.000ZTHX PHARMA REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026https://www.pharmaradar360.com/article/investing-in-immunisation-strengthening-europe-s-competitiveness-resilience-and-849432e73f7ed88cPharmaRadar360en2026-09-29T16:16:11.000ZInvesting in immunisation: Strengthening Europe’s Competitiveness, Resilience and Global Health Securityhttps://www.pharmaradar360.com/article/fda-recalls-and-warnings-blood-pressure-drug-recalled-for-second-time-in-3-month-03aceda915aff5fcPharmaRadar360en2026-09-29T16:15:20.000ZFDA Recalls and Warnings: Blood Pressure Drug Recalled for Second Time in 3 Months; Some GLP-1 Pens May Contain No Medicationhttps://www.pharmaradar360.com/article/get-in-losers-we-re-stockpiling-mifepristone-b912862477dc724ePharmaRadar360en2026-09-29T16:11:22.000ZGet In Losers, We’re Stockpiling Mifepristonehttps://www.pharmaradar360.com/article/guidance-the-centres-of-excellence-for-regulatory-science-and-innovation-program-7e43fa3f03ad1950PharmaRadar360en2026-09-29T16:01:29.000ZGuidance: The Centres of Excellence for Regulatory Science and Innovation programme (CERSIs)https://www.pharmaradar360.com/article/biotech-execs-go-to-washington-053fef2ae1a55f16PharmaRadar360en2026-09-29T16:00:00.000ZBiotech execs go to Washingtonhttps://www.pharmaradar360.com/article/why-is-medicure-stock-up-4-41-as-its-phase-3-drug-trial-reaches-a-key-milestone-e227a3e400507896PharmaRadar360en2026-09-29T15:54:20.000ZWhy Is Medicure Stock Up 4.41% as Its Phase 3 Drug Trial Reaches a Key Milestone? (TSXV:MPH)https://www.pharmaradar360.com/article/cordis-project-driving-sustainable-innovation-to-minimise-pfas-in-european-healt-c169b65ac0c6323ePharmaRadar360en2026-09-29T15:50:25.000ZCORDIS project: Driving Sustainable Innovation to Minimise PFAS in European Healthcarehttps://www.pharmaradar360.com/article/digitising-adult-social-care-d547f046fbc877bfPharmaRadar360en2026-09-29T15:50:09.000ZDigitising adult social carehttps://www.pharmaradar360.com/article/cordis-project-doctoral-training-network-on-glycan-cancer-microbiota-interaction-9ad6d2c3d1eb9ba8PharmaRadar360en2026-09-29T15:50:07.000ZCORDIS project: Doctoral Training Network on Glycan–Cancer–Microbiota Interactions for Therapeutic and Diagnostic Innovation in Colorectal cancerhttps://www.pharmaradar360.com/article/cordis-project-improved-diagnosis-monitoring-and-treatment-through-european-doct-6144e9f615004bd0PharmaRadar360en2026-09-29T15:50:06.000ZCORDIS project: Improved Diagnosis, Monitoring and Treatment through European Doctoral Collaboration in Capsule Endoscopyhttps://www.pharmaradar360.com/article/level-5-award-in-understanding-digital-leadership-in-adult-social-care-qualifica-72d84911d1d35251PharmaRadar360en2026-09-29T15:49:54.000ZLevel 5 Award in Understanding Digital Leadership in Adult Social Care qualificationhttps://www.pharmaradar360.com/article/digital-champions-in-adult-social-care-and-how-to-introduce-them-a82385a4dccd195ePharmaRadar360en2026-09-29T15:49:39.000ZDigital champions in adult social care and how to introduce themhttps://www.pharmaradar360.com/article/adult-social-care-digital-skills-framework-3e1f364a98b45773PharmaRadar360en2026-09-29T15:49:21.000ZAdult social care digital skills frameworkhttps://www.pharmaradar360.com/article/using-ai-in-adult-social-care-160ed4ac7167e8a1PharmaRadar360en2026-09-29T15:48:57.000ZUsing AI in adult social carehttps://www.pharmaradar360.com/article/cordis-project-fortify-framework-for-optimized-regulation-trade-secrets-and-inte-51518399da124585PharmaRadar360en2026-09-29T15:48:45.000ZCORDIS project: FORTIFY - FRAMEWORK FOR OPTIMIZED REGULATION, TRADE SECRETS, AND INTELLECTUAL PROPERTY IN A FEDERATED EUROPEAN HEALTH DATA SPACEhttps://www.pharmaradar360.com/article/choosing-and-managing-software-and-it-suppliers-as-an-adult-social-care-provider-5d1edb4427be00f2PharmaRadar360en2026-09-29T15:48:40.000ZChoosing and managing software and IT suppliers as an adult social care providerhttps://www.pharmaradar360.com/article/becoming-a-fully-digitised-care-provider-850a3247d9638018PharmaRadar360en2026-09-29T15:48:14.000ZBecoming a fully digitised care providerhttps://www.pharmaradar360.com/article/cordis-project-european-pediatric-immunotherapy-trial-with-combinatory-atmps-for-7a15183cc9d1c9f1PharmaRadar360en2026-09-29T15:48:07.000ZCORDIS project: European Pediatric Immunotherapy Trial with Combinatory ATMPs for DIPGhttps://www.pharmaradar360.com/article/digital-social-care-records-choosing-and-implementing-solutions-9ff6e76c8523735fPharmaRadar360en2026-09-29T15:47:51.000ZDigital social care records: choosing and implementing solutionshttps://www.pharmaradar360.com/article/setting-up-and-using-secure-email-as-an-adult-social-care-provider-2816854da8b19150PharmaRadar360en2026-09-29T15:47:32.000ZSetting up and using secure email as an adult social care providerhttps://www.pharmaradar360.com/article/using-smartphones-and-devices-as-an-adult-social-care-provider-84e7b171d1648e02PharmaRadar360en2026-09-29T15:47:10.000ZUsing smartphones and devices as an adult social care providerhttps://www.pharmaradar360.com/article/setting-up-your-internet-as-an-adult-social-care-provider-2c0ec07c98b58436PharmaRadar360en2026-09-29T15:46:49.000ZSetting up your internet as an adult social care providerhttps://www.pharmaradar360.com/article/cordis-project-integrated-services-for-infectious-disease-outbreak-research-ii-2d7d22efb5ba91fcPharmaRadar360en2026-09-29T15:45:11.000ZCORDIS project: INTEGRATED SERVICES FOR INFECTIOUS DISEASE OUTBREAK RESEARCH IIhttps://www.pharmaradar360.com/article/cordis-project-a-holistic-neuroarchitectural-approach-to-child-centred-healthcar-7defb4f73f8c3453PharmaRadar360en2026-09-29T15:44:05.000ZCORDIS project: A Holistic Neuroarchitectural Approach to Child-Centred Healthcare Design: A Multimodal Framework Using Mixed Reality and Artificial Intelligencehttps://www.pharmaradar360.com/article/cordis-project-protein-ligand-data-generation-at-scale-to-support-computational-5f4922b9d8f0eaccPharmaRadar360en2026-09-29T15:43:14.000ZCORDIS project: Protein-ligand data generation at scale to support computational hit finding and optimizationhttps://www.pharmaradar360.com/article/fda-concerns-unapproved-glp-1-drugs-weight-loss-summary-e984d86f9c2a2937PharmaRadar360en2026-09-29T15:27:34.000Zfda concerns unapproved glp 1 drugs weight loss summaryhttps://www.pharmaradar360.com/article/us-details-rules-for-0-specialty-pharmaceutical-tariff-exemptions-57d00b4fc896009aPharmaRadar360en2026-09-29T15:22:05.000ZUS details rules for 0% specialty pharmaceutical tariff exemptionshttps://www.pharmaradar360.com/article/pbs-biotech-industrializes-cell-therapy-development-with-rockwell-automation-0a94bf6091daf6fePharmaRadar360en2026-09-29T15:00:00.000ZPBS Biotech Industrializes Cell Therapy Development with Rockwell Automationhttps://www.pharmaradar360.com/article/pertussis-background-information-on-prevention-and-management-5d3042eabd34aac1PharmaRadar360en2026-09-29T14:53:29.000ZPertussis: background information on prevention and managementhttps://www.pharmaradar360.com/article/field-safety-notices-21-to-25-september-2026-078ecce4bd7aeb53PharmaRadar360en2026-09-29T14:49:41.000ZField Safety Notices: 21 to 25 September 2026https://www.pharmaradar360.com/article/fda-tainted-weight-loss-products-hidden-drug-ingredients-list-5d82947e2237a8cdPharmaRadar360en2026-09-29T14:24:43.000Zfda tainted weight loss products hidden drug ingredients listhttps://www.pharmaradar360.com/article/biotech-etf-sbio-can-get-its-groove-back-96826db02b78fcb6PharmaRadar360en2026-09-29T14:12:33.000ZBiotech ETF SBIO Can Get Its Groove Backhttps://www.pharmaradar360.com/article/uniqure-stock-crashes-as-huntington-s-gene-therapy-data-weaken-b19a7b628fe9bfebPharmaRadar360en2026-09-29T13:28:42.000ZuniQure stock crashes as Huntington’s gene therapy data weakenhttps://www.pharmaradar360.com/article/mhra-safety-roundup-september-2026-4113d0c7fbae5b14PharmaRadar360en2026-09-29T13:12:24.000ZMHRA Safety Roundup: September 2026https://www.pharmaradar360.com/article/lsi-alumni-innovator-spotlight-orchestra-biomed-s-david-hochman-darren-sherman-a-340f712d4b6d5d2aPharmaRadar360en2026-09-29T13:03:53.000ZLSI Alumni Innovator Spotlight: Orchestra BioMed’s David Hochman, Darren Sherman, and Bill Littlehttps://www.pharmaradar360.com/article/abbvie-partners-with-valkai-to-apply-advanced-ai-across-targeted-areas-of-clinic-ea706a513a127cf7PharmaRadar360en2026-09-29T13:00:00.000ZAbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Developmenthttps://www.pharmaradar360.com/article/guidance-medicines-that-you-cannot-export-from-the-uk-or-hoard-c5cda515f87d09b2PharmaRadar360en2026-09-29T12:36:57.000ZGuidance: Medicines that you cannot export from the UK or hoardhttps://www.pharmaradar360.com/article/keros-therapeutics-expects-20-million-milestone-payment-after-first-patient-dose-dd5e9ca5b0ce2d06PharmaRadar360en2026-09-29T12:13:00.000ZKeros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 Trialhttps://www.pharmaradar360.com/article/biotech-open-platform-inaugurates-its-biotechnology-platform-opening-a-new-chapt-07df4ef44aa99d71PharmaRadar360en2026-09-29T12:04:05.000ZBiotech Open Platform inaugurates its biotechnology platform, opening a new chapter for industrial innovation in Europehttps://www.pharmaradar360.com/article/heartburn-medicine-taken-only-when-symptoms-strike-is-being-tested-in-a-new-stud-cb108faff325b090PharmaRadar360en2026-09-29T12:00:00.000ZHeartburn medicine taken only when symptoms strike is being tested in a new study.https://www.pharmaradar360.com/article/publication-of-roads-phase-3-clinical-trial-data-in-journal-of-clinical-oncology-b9336ebe78e0b1b9PharmaRadar360en2026-09-29T12:00:00.000ZPublication of ROADS Phase 3 Clinical Trial Data in Journal of Clinical Oncology Recommends GammaTile® as a New Standard-of-Care Option for Newly Diagnosed Operable Brain Metastases1https://www.pharmaradar360.com/article/a-calgary-trial-will-test-psychedelic-therapy-for-ptsd-in-survivors-of-partner-v-979d4778256f2373PharmaRadar360en2026-09-29T11:53:00.000ZA Calgary trial will test psychedelic therapy for PTSD in survivors of partner violencehttps://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662PharmaRadar360en2026-09-29T11:46:18.000ZAnnual flu programmehttps://www.pharmaradar360.com/article/why-do-i-have-to-wait-for-my-flu-vaccine-137fa17330735ce3PharmaRadar360en2026-09-29T11:45:58.000ZWhy do I have to wait for my flu vaccine?https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-19-december-2027-week-52-b8a45580b6a89dc8PharmaRadar360en2026-09-29T11:29:32.000ZWeekly all-cause mortality surveillance: week ending 19 December 2027 (week 52)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-12-december-2027-week-51-8bbe5b9ad00f0824PharmaRadar360en2026-09-29T11:28:57.000ZWeekly all-cause mortality surveillance: week ending 12 December 2027 (week 51)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-5-december-2027-week-50-ec3574994fc6b12cPharmaRadar360en2026-09-29T11:28:24.000ZWeekly all-cause mortality surveillance: week ending 5 December 2027 (week 50)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-28-november-2027-week-49-03f725160579e289PharmaRadar360en2026-09-29T11:27:52.000ZWeekly all-cause mortality surveillance: week ending 28 November 2027 (week 49)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-21-november-2027-week-48-906ff186b83f3d26PharmaRadar360en2026-09-29T11:27:20.000ZWeekly all-cause mortality surveillance: week ending 21 November 2027 (week 48)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-14-november-2027-week-47-220b2a9a2f3d2ba2PharmaRadar360en2026-09-29T11:26:43.000ZWeekly all-cause mortality surveillance: week ending 14 November 2027 (week 47)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-7-november-2027-week-46-130ceb19d00b34edPharmaRadar360en2026-09-29T11:26:10.000ZWeekly all-cause mortality surveillance: week ending 7 November 2027 (week 46)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-31-october-2027-week-45-816ba09c4e2b94adPharmaRadar360en2026-09-29T11:25:39.000ZWeekly all-cause mortality surveillance: week ending 31 October 2027 (week 45)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-24-october-2027-week-44-49db0cf94f13c9c3PharmaRadar360en2026-09-29T11:25:04.000ZWeekly all-cause mortality surveillance: week ending 24 October 2027 (week 44)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-17-october-2027-week-43-1377412a794bddb0PharmaRadar360en2026-09-29T11:24:32.000ZWeekly all-cause mortality surveillance: week ending 17 October 2027 (week 43)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-10-october-2027-week-42-a35bcc7dd40ea4dcPharmaRadar360en2026-09-29T11:24:02.000ZWeekly all-cause mortality surveillance: week ending 10 October 2027 (week 42)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-26-september-2027-week-40-cafab225ca585d99PharmaRadar360en2026-09-29T11:22:58.000ZWeekly all-cause mortality surveillance: week ending 26 September 2027 (week 40)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-19-september-2027-week-39-9b2d980f683475baPharmaRadar360en2026-09-29T11:22:46.000ZWeekly all-cause mortality surveillance: week ending 19 September 2027 (week 39)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-12-september-2027-week-38-5624472768f61b46PharmaRadar360en2026-09-29T11:22:30.000ZWeekly all-cause mortality surveillance: week ending 12 September 2027 (week 38)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-3-october-2027-week-41-d566271315b7411aPharmaRadar360en2026-09-29T11:22:01.000ZWeekly all-cause mortality surveillance: week ending 3 October 2027 (week 41)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-5-september-2027-week-37-e7f3c7cbaa3cbc4cPharmaRadar360en2026-09-29T11:18:12.000ZWeekly all-cause mortality surveillance: week ending 5 September 2027 (week 37)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-29-august-2027-week-36-918bc37c0ef8e86dPharmaRadar360en2026-09-29T11:17:35.000ZWeekly all-cause mortality surveillance: week ending 29 August 2027 (week 36)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-22-august-2027-week-35-8ce50626c5622aedPharmaRadar360en2026-09-29T11:16:57.000ZWeekly all-cause mortality surveillance: week ending 22 August 2027 (week 35)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-15-august-2027-week-34-cdafc67049bd8f8dPharmaRadar360en2026-09-29T11:16:19.000ZWeekly all-cause mortality surveillance: week ending 15 August 2027 (week 34)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-8-august-2027-week-33-83d3cb74aa57d84ePharmaRadar360en2026-09-29T11:15:47.000ZWeekly all-cause mortality surveillance: week ending 8 August 2027 (week 33)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-1-august-2027-week-32-531f24604ee7252cPharmaRadar360en2026-09-29T11:15:08.000ZWeekly all-cause mortality surveillance: week ending 1 August 2027 (week 32)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-25-july-2027-week-31-f22ac5b2a850b654PharmaRadar360en2026-09-29T11:14:14.000ZWeekly all-cause mortality surveillance: week ending 25 July 2027 (week 31)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-18-july-2027-week-30-9bbd2f39861d09cfPharmaRadar360en2026-09-29T11:13:40.000ZWeekly all-cause mortality surveillance: week ending 18 July 2027 (week 30)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-11-july-2027-week-29-1166371222fe3f08PharmaRadar360en2026-09-29T11:12:19.000ZWeekly all-cause mortality surveillance: week ending 11 July 2027 (week 29)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-4-july-2027-week-28-318464a5f5825846PharmaRadar360en2026-09-29T11:11:40.000ZWeekly all-cause mortality surveillance: week ending 4 July 2027 (week 28)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-27-june-2027-week-27-d34044d835b27467PharmaRadar360en2026-09-29T11:11:03.000ZWeekly all-cause mortality surveillance: week ending 27 June 2027 (week 27)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-20-june-2027-week-26-63a9b6e8e85f4966PharmaRadar360en2026-09-29T11:10:29.000ZWeekly all-cause mortality surveillance: week ending 20 June 2027 (week 26)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-13-june-2027-week-25-38a4604f6f3c4dbbPharmaRadar360en2026-09-29T11:09:53.000ZWeekly all-cause mortality surveillance: week ending 13 June 2027 (week 25)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-6-june-2027-week-24-445734c41de6d04ePharmaRadar360en2026-09-29T11:08:48.000ZWeekly all-cause mortality surveillance: week ending 6 June 2027 (week 24)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-30-may-2027-week-23-9a3ae8892724e43ePharmaRadar360en2026-09-29T11:08:09.000ZWeekly all-cause mortality surveillance: week ending 30 May 2027 (week 23)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-23-may-2027-week-22-75936d007f16d912PharmaRadar360en2026-09-29T11:07:33.000ZWeekly all-cause mortality surveillance: week ending 23 May 2027 (week 22)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-16-may-2027-week-21-3d36b06084c820f3PharmaRadar360en2026-09-29T11:06:44.000ZWeekly all-cause mortality surveillance: week ending 16 May 2027 (week 21)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-9-may-2027-week-20-09f438d015f24d7aPharmaRadar360en2026-09-29T11:06:05.000ZWeekly all-cause mortality surveillance: week ending 9 May 2027 (week 20)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-2-may-2027-week-19-2e326d95d3d5c019PharmaRadar360en2026-09-29T11:05:09.000ZWeekly all-cause mortality surveillance: week ending 2 May 2027 (week 19)https://www.pharmaradar360.com/article/about-221-patients-are-expected-to-enroll-in-china-with-an-investor-helping-fund-1f084d1e40dc713cPharmaRadar360en2026-09-29T11:04:22.000ZAbout 221 patients are expected to enroll in China, with an investor helping fund the lung cancer trial.https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-25-april-2027-week-18-7c119c48bde6ca47PharmaRadar360en2026-09-29T11:04:19.000ZWeekly all-cause mortality surveillance: week ending 25 April 2027 (week 18)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-18-april-2027-week-17-61e0d957befbc612PharmaRadar360en2026-09-29T11:03:19.000ZWeekly all-cause mortality surveillance: week ending 18 April 2027 (week 17)https://www.pharmaradar360.com/article/in-a-trial-56-5-had-an-adverse-event-injection-reaction-or-allergy-with-invivyd-1ca8449e4e9a91a8PharmaRadar360en2026-09-29T11:01:00.000ZIn a trial, 56.5% had an adverse event, injection reaction or allergy with Invivyd's COVID antibody, versus 91.4% with an mRNA vaccine.https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-11-april-2027-week-16-ca3f873b714c8310PharmaRadar360en2026-09-29T11:00:48.000ZWeekly all-cause mortality surveillance: week ending 11 April 2027 (week 16)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-4-april-2027-week-15-ce1c58e5f998d36fPharmaRadar360en2026-09-29T10:59:49.000ZWeekly all-cause mortality surveillance: week ending 4 April 2027 (week 15)https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-1b4c313e4093d4bbPharmaRadar360en2026-09-29T10:59:25.000ZAdult social care client level data, England: quarterly updatehttps://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-march-2026-f6bcfb810bad2e74PharmaRadar360en2026-09-29T10:59:08.000ZAdult social care client level data, England: quarterly update to March 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-28-march-2027-week-14-fce9bba549e24234PharmaRadar360en2026-09-29T10:59:02.000ZWeekly all-cause mortality surveillance: week ending 28 March 2027 (week 14)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-21-march-2027-week-13-3bc55aa6606b07f8PharmaRadar360en2026-09-29T10:57:32.000ZWeekly all-cause mortality surveillance: week ending 21 March 2027 (week 13)https://www.pharmaradar360.com/article/china-acetonitrile-market-tightens-as-glp-1-api-production-drives-demand-2be736315a8a8ce9PharmaRadar360en2026-09-29T10:57:32.000ZChina Acetonitrile Market Tightens as GLP-1 API Production Drives Demandhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-14-march-2027-week-12-59f14363f8f5e93bPharmaRadar360en2026-09-29T10:56:53.000ZWeekly all-cause mortality surveillance: week ending 14 March 2027 (week 12)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-7-march-2027-week-11-3ed26e34062d9b47PharmaRadar360en2026-09-29T10:56:06.000ZWeekly all-cause mortality surveillance: week ending 7 March 2027 (week 11)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-28-february-2027-week-10-b24ebd3685f4e740PharmaRadar360en2026-09-29T10:55:04.000ZWeekly all-cause mortality surveillance: week ending 28 February 2027 (week 10)https://www.pharmaradar360.com/article/la-aemps-informa-de-un-error-de-embalaje-en-un-lote-de-apositos-aquacel-foam-pro-1b33bfa56e7f6818PharmaRadar360en2026-09-29T10:49:55.000ZLa AEMPS informa de un error de embalaje en un lote de apósitos Aquacel Foam Prohttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-21-february-2027-week-9-3c8feae5609ae716PharmaRadar360en2026-09-29T10:46:41.000ZWeekly all-cause mortality surveillance: week ending 21 February 2027 (week 9)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-14-february-2027-week-8-b16d8a4c5c1a754dPharmaRadar360en2026-09-29T10:45:18.000ZWeekly all-cause mortality surveillance: week ending 14 February 2027 (week 8)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-7-february-2027-week-7-9768c2ec72a62b4cPharmaRadar360en2026-09-29T10:44:42.000ZWeekly all-cause mortality surveillance: week ending 7 February 2027 (week 7)